Globally, around 3 billion cups of coffee are drank daily, according to estimates. Due to its high caffeine concentration, it is frequently used to enhance alertness and productivity. Past research has demonstrated that frequent coffee drinking is associated with a number of health benefits.
Around 30% of people worldwide suffer from non-alcoholic fatty liver disease (NAFLD), one of the most prevalent liver diseases. Cirrhosis and cancer can develop over time as a result of the accumulation of excess fat in the liver.
Recently, researchers from Mahidol University in Thailand published a research paper entitled " Coffee Consumption and Non-alcoholic Fatty Liver Disease: An Umbrella Review and a Systematic Review and Meta-analysis". This study showed that coffee intake was significantly associated with a reduction in liver fibrosis in patients with NAFLD, with a 33% reduction in liver fibrosis in coffee drinkers.
The study involved a thorough review of 16 research publications with more than 170,000 individuals to determine the association between coffee consumption and the prevalence of nonalcoholic fatty liver disease and decreased liver fibrosis.
First, data analysis revealed that coffee consumption was not linked to a decreased incidence of NAFLD in the general population after researchers examined nine studies on the impact of coffee consumption on the incidence of NAFLD, totaling 147,875 individuals.
In comparison to non-coffee users, neither drinking one cup of coffee per day nor more was linked to a lower prevalence of NAFLD in the general population.
Further, coffee intake and liver fibrosis in patients with NAFLD were analyzed, comprising a total of 5 studies that included 2,948 patients with NAFLD.
The results showed that coffee intake was significantly associated with a reduction in liver fibrosis, with a 33% reduction in liver fibrosis in coffee drinkers.
The researchers then analyzed the coffee consumption of the general population and NAFLD patients, including a total of 19,482 people in four observational studies, including 17,322 in the general population and 2,160 with NAFLD.
The study found that the general population did not consume more coffee than people with NAFLD.
Finally, the researchers analyzed the differences in coffee intake among NAFLD patients with no/mild and severe liver fibrosis stages through four observational studies. Of the 3,331 patients, 2,912 had no/mild fibrosis, while 419 had significant fibrosis.
Pooled results showed no difference in coffee intake between the two groups of patients with different stages of fibrosis.
The researchers made the following claims about coffee's hepatoprotective mechanism:
1. An in vitro investigation revealed that caffeine lowers liver inflammation and oxidative stress. Moreover, hepatocytes that were exposed to its method of action exhibited symptoms of antifibrotic characteristics.
2. According to other research, a variety of coffee's non-caffeinated components also possess anti-inflammatory antioxidant capabilities.
3. Antioxidants play a significant part in lowering lipid buildup in hepatocytes in addition to their anti-inflammatory actions.
In conclusion, research has demonstrated that coffee can help NAFLD patients by lowering liver fibrosis.
With presently no drugs or therapies for NAFLD, lifestyle changes like shedding pounds and drinking coffee seem to be viable prevention options, but research on therapeutics should not pause, of which a critical step is to determine the ideal biomarker.
Particularly for differentiating NASH from straightforward steatosis and assessing the likelihood of disease development, the optimal biomarkers should be simple to measure, repeatable, inexpensive, and precise. Such biomarkers would enable noninvasive, regular monitoring of the disease's development and therapeutic response in addition to helping clinicians identify individuals with NASH. Indicators of hepatocyte apoptosis, oxidative stress, and inflammation are among these biomarkers, along with prediction models based on clinical parameters. Extracellular vesicles (EVs) have also been linked to possible biomarkers for NASH diagnosis based on their biogenesis and composition.
Source: https://www.creative-biolabs.com/nash-therapy/development-service-of-bio...
JERRY CARTER